Oncology

An expert shares information on risk factors and controversies around testing.

Pharmacologic approaches can reduce the risk of chronic GVHD.

Positive data on the novel prostate cancer combination treatment was presented at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium.

Olaparib with abiraterone increased survival in patients with metastatic prostate cancer compared to the current standard of care, according to a session at the ASCO Genitourinary Cancers Symposium.

The FDA approved darolutamide in 2019 for the treatment of patients with nonmetastatic castration-resistant prostate cancer based improved metastasis-free survival.

Oncology pharmacists are as diverse as the cancers they manage and have key roles in the following areas of the cancer care continuum.

Each therapy presents a different but effective treatment option.

Pharmacists can be involved in all aspects of care, from deciding treatment plans to educating patients, and in the growing role of oral treatments.

Incidence of regional tumor recurrence in patients with HR–positive breast cancer did not significantly differ between patients who received post operational radiotherapy.

Novel drug development has been focused on the augmentation of the T-lymphocyte response.

Because of CRS and neurologic toxicity risk, the therapy is available through a REMS program.

New data identifying a particular gene expression signature will be presented at the 2023 ASCO Genitourinary Symposium.

Both indications for the CTLA-4 inhibitor were approved by the FDA in 2022.

The drive for personalized approaches to cancer have helped to create treatments for patients with rare cancers who have few, if any, options.

Idecabtagene vicleucel prolonged progression-free survival by more than 1 year in a difficult-to-treat patient population with relapsed or refractory multiple myeloma.

HER2-low disease demands a different approach from that of HER2-negative disease.

The patient's list of medications reveals significant drug interactions to be addressed.

Trial meets its primary endpoint of progression-free survival regardless of mismatch repair status in patients with stage 3 or 4 or recurrent endometrial carcinoma.

By binding to and inhibiting RANKL, denosumab decreases the production and activity of osteoclasts, resulting in reduced bone loss.

Earlier this week, the FDA Oncologic Drugs Advisory Committee also voted 8 to 5 in support of data for dostarlimab-gxly in rectal cancer.

PARP inhibitors in particular have changed the therapeutic landscape for EOC.

Several studies have noted a potential link between methotrexate and an increased risk of skin cancer.

Numerous clinical trials are investigating the next generation of PARPi.

Cancer screening rates were still below the expected rates of return in both 2021 and 2022.

Investigators hope that new findings can cultivate new methods of facilitating immune response to attack lung tumors.

In a fact sheet released by the White House, President Joseph Biden called a $35 monthly cap on insulin for all Americans a “commonsense, life-saving protection.”

Approval of a novel antibody-drug conjugate ushers in new second-line option.

These agents are likely to become the mainstay of cancer treatment in the very near future.

Isatuximab and daratumumab offer promising treatment options for previously treated multiple myeloma.

Patients with triple-negative breast cancer treated with veliparib had statistically significantly longer survival than those given placebo.